British American Tobacco p.l.c. (BATS) Earnings Call Transcript & Summary
July 31, 2025
Earnings Call Speaker Segments
Tadeu Marroco
executiveGood morning, everyone. It's a pleasure to have you join us for the presentation of our 2025 interim results. Joining me this morning are Soraya Benchikh, our CFO, and Victoria Buxton, Group Head of Investor Relations. I'll start by covering the transformation highlights and how we're progressing against our 2025 priorities. After that, Soraya will walk you through the financial results in greater detail. Before I come back, she'll share more on the performance outlook and explain why we're confident about the pathway ahead. Then we'll take your questions. With that, please turn your attention to the disclaimers on slides two and three. Let's start by examining the positive transformation momentum we're driving. Beginning with a few highlights: we've delivered group results slightly ahead of expectations, and Soraya will cover that in more detail. Smokeless now represents 18.2% of group revenue, an increase of 70 basis points versus last year, and we added 1.4 million smokeless consumers, reaching 30.5 million, mainly driven by our continued success in Modern Oral. Our focus on quality growth, balancing top and bottom-line delivery, has driven a further improvement in new category contribution margin, up 280 basis points to 10.6% at constant rates. We continue to enhance our financial flexibility, enabling us to make progress on the leverage and reward shareholders with strong cash returns.
Tadeu Marroco
executiveOn top of our progressive dividends, we've recently raised the 2025 share buyback by GBP 200 million—to GBP 1.1 billion. In the first half, against our 2025 priorities, I'm proud that we've delivered what we said we would, and we keep building a track record of delivery. Our focus on quality growth sits at the heart of how we execute in new categories, making sure new innovations are rolled out in a targeted way while we go on improving our contribution margin. Generating value from our combustibles business is essential for funding the transformation, and the U.S. is a key driver of that. I'm delighted that in the U.S. we've returned to growth in both revenue and profit for the first time since 2022, driven by combustibles and Modern Oral. We stay focused on our proactive approach to regulatory affairs and keep advocating for science-led, level playing fields, with robust enforcement, for smokeless alternatives. During the first half, we activated Omni in 13 markets globally, with more launches planned for the second half of the year. Importantly, all of this is carried out with a strong emphasis on cash generation, which lets us keep leveraging and rewarding shareholders with strong cash returns. I'm pleased to report a notable rise in energy and momentum across the group, and I want to thank all our teams around the world who are driving these encouraging results.
Tadeu Marroco
executiveHaving said that, I'll now pass things over to Soraya, who will walk you through how we performed in H1 in greater detail.
Soraya Benchikh
executiveThank you, Tadeu, and good morning to everybody. I'm happy to report that, on a constant currency basis, our results landed slightly above what had been expected. The figures we reported contain certain adjusting items — for example, a GBP 575 million reduction to our Canadian provision, made after we updated the forecasted market performance, plus a GBP 900 million gain on the partial sale of our ITC investment. So that you get a clear picture of underlying performance, my focus will be on constant currency-adjusted metrics; further detail on those adjusting items and on market share data is available in the appendix. During H1 we delivered a strong performance that ran ahead of our original guidance, sitting at the upper end of our 1%-2% revenue growth range. Group revenue increased 1.8%. Adjusted gross profit climbed 3%, adjusted profit from operations was up 1.9%, and adjusted diluted EPS rose 1.7%. Given a stronger-than-expected H1, we now expect full-year revenue to land at the top end of our 1%-2% guidance. Our upfill guidance stays at 1.5%-2.5%, which reflects greater investment in new categories and a stronger U.S. combustibles competitor in H2. Let's move on now to new categories. Revenue there grew 2.4%, powered by outstanding growth in Modern Oral — up over 40% — and in Heated Products, which increased by more than 3%.
Soraya Benchikh
executivePart of that was counterbalanced by a 13% drop in vapor, driven largely by illicit trade in the U.S. and Canada. Our growth is quality growth: gross margin rose 250 basis points and contribution margin climbed 280 basis points, hitting 10.6%. That comes from targeted investments in high-value markets, a disciplined approach to ROI, and the advantages of scale. The progress we've achieved makes me genuinely proud, and we anticipate momentum strengthening in H2, with new category revenue growth reaching the mid-single digits for the full year. Modern Oral in AME stands as a great illustration of quality growth in action. We hold clear category leadership in the region, with 63% volume share in top markets. Across the last four years, consumer numbers, volume, and revenue have all more than tripled, which makes Modern Oral our biggest new category in the region by both revenue and contribution, with a gross margin already 10 percentage points above combustibles, along with the quickest payback period at just over one year. Going forward, I have confidence that Modern Oral will remain a key engine of our sustainable growth and profitability, both in AME and globally. Turning now to combustibles, revenue grew 0.8%, as volume decline was more than offset by strong pricing around the world, producing a healthy price mix uplift.
Soraya Benchikh
executiveWe also achieved quality growth in this area. Gross profit went up 2.4%, while contribution climbed 2.2%, supported by solid U.S. performance, favorable price mix, and continued productivity and simplification benefits. It's particularly encouraging to see our U.S. combustibles business growing again — the first time that's happened since 2022. That shows how resilient our combustibles portfolio is and gives us greater confidence in meeting our midterm targets. Turning to the U.S., I'm very happy to report that we're back to growth in both revenue and profit. Within combustibles, a better portfolio and stronger execution — including improved revenue growth management — produced a 3.8% revenue increase as we lapped last year's investment cycle. Volume share gained 10 basis points, and value share gained 20. Leaving out the deep discount segment, where we have no presence, volume share was 60 basis points higher. In new categories, revenue was up 3.9%, fueled by the successful launch of Velo Plus, which generated more than 380% growth in Modern Oral revenue. That was partly offset by a 12.3% drop in vapor, hit by continuing illicit single-use products. On the whole, U.S. revenue rose 3.7% and adjusted profit was up 3.2%, driven by combustibles, though partly offset by Vuse headwinds and investment in Velo Plus.
Soraya Benchikh
executiveTadeu is going to cover the U.S. in more detail in a moment. AME turned in another strong half. Revenue climbed 3.5%, and combustibles were up almost 3%, helped by robust volumes in Brazil and Turkey along with solid pricing. New category revenue was up 1.3%, which includes growth of nearly 17% in Modern Oral, a segment where our volume share stands at 63%. Those gains were offset by illicit vapor in Canada and by shifting market dynamics following single-use vapor bans in certain large markets. Growth in Heated Products across Poland and Portugal was more than outweighed by the effect of resource allocation decisions in the Czech Republic, Germany, and Romania. Adjusted operating profit was up more than 10%, running well ahead of revenue, and that was driven by operating leverage and efficiency gains in combustibles, scale benefits and resource allocation in new categories, plus our accounting treatment for Canada. AME really is a multi-category region, and it is delivering quality growth. Over in ATMEA, fiscal and regulatory headwinds in Bangladesh and Australia more than offset good performances in Pakistan and Nigeria. Total revenue declined 4.8%, and combustibles fell 7.9%. New category revenue rose 2.5%, driven by Heated Products growth in Japan and Modern Oral gains in emerging markets, partly offset by vapor, which felt the impact of strategic market exits as we moved our focus toward more profitable opportunities.
Soraya Benchikh
executiveAdjusted operating profit fell 12.3%, largely because of the difficulties we faced in Bangladesh and Australia. Our operating margin stayed level, as we countered inflation and FX headwinds, helped by a robust U.S. performance, improved profitability in new categories, and ongoing cost reductions. At today's rates, operating margin rose 20 basis points. BAT has a solid history of delivering cost savings, and we keep adding to that record. From 2023 onward, we have achieved close to GBP 900 million in productivity savings and expect to surpass GBP 1.2 billion by the end of the year. Those savings assist us in handling inflation and foreign exchange effects while also financing innovation in new categories. During H1, we took on GBP 166 million of inflation-related costs plus a 1% transactional FX headwind on adjusted operating profit. Beyond 2025, our focus stays on simplifying combustibles and scaling new categories, with a target of an additional GBP 2 billion in cost of goods sold savings by 2030. To push agility and savings further, I'm delighted to launch our new Fit to Win program. Fit to Win is a 3-year initiative built to simplify how we work, boost agility, and embed digital decision-making. Although we are still in the planning stage, we are confident it will deliver roughly GBP 500 million in annualized savings by the close of 2028.
Soraya Benchikh
executiveThe savings we're generating will back our growth algorithm and help fund the investments that fuel long-term profit and cash flow. And importantly, this comes on top of the GBP 2 billion COGS target we set out at our capital markets day last year. We're expecting associated costs of GBP 500 million across the next two years, and since this is a one-time investment, GBP 350 million of that will be treated as adjusting, beginning in 2025 and running through 2027. I'll go into more detail when we report full-year results in February. Earnings per share increased 1.7%. Lower share counts helped support that growth, but it was offset by our reduced share of ITC profits as well as higher net finance costs. Our underlying tax rate came in at 24.4%, and for the full year we expect a rate of around 25%, assuming no major shifts in prevailing tax rates. Translational FX was driven by sterling strength against most major global currencies, with the weakening U.S. dollar accounting for roughly 50% of this headwind. Strong cash generation keeps enhancing our financial flexibility. We're on track to deliver more than GBP 50 billion in free cash flow by the end of 2030. Our focus stays on capital allocation priorities: investing in transformation, balancing deleveraging with progressive dividends and sustainable share buybacks, and selective bolt-on M&A to support that transformation.
Soraya Benchikh
executiveDuring May, we raised the 2025 GBP buyback by GBP 200 million to GBP 1.1 billion, and GBP 650 million of that is set aside for the second half. Overall, H1 came in above expectations, and the momentum we are building during this deployment year gives us confidence that we will deliver our full-year guidance. Among the main growth drivers are continued strength in the U.S., led by combustibles and Velo Plus; faster new category revenue as glo Hilo and Vuse Ultra roll out; and Velo, which keeps strong global momentum along with further gains in new category contribution. Given a stronger-than-expected H1, we now expect full-year revenue at the top end of our 1%-2% guidance. We are keeping our upfill guidance at 1.5%-2.5%, which reflects more investment in new categories, a stronger U.S. combustibles competitor in H2, and a 1%-1.5% transactional FX headwind. All of this lets us put more into innovation while remaining firmly on track for 2026. Our H1 results demonstrate strong progress across several drivers, which reinforces my confidence in getting back to our midterm algorithm of 3%-5% revenue growth and 4%-6% operating profit growth. Excluding the regulatory and fiscal headwinds in Bangladesh and Australia, we are already reaching the lower end of our midterm targets, with 3% revenue growth and 4.5% operating profit growth.
Soraya Benchikh
executiveBeyond that, what's also giving me encouragement are the initial signals from the launch of our premium innovations, and Tadeu will now cover those in greater detail.
Tadeu Marroco
executiveThank you, Soraya. I'd like to lay out why we feel confident about the road ahead. The nicotine sector is changing quickly and expanding, as adult consumers across the globe increasingly move into new categories. From the very beginning we have followed a multi-category strategy, and that leaves us strongly positioned to gain from these consumer trends. Drawing on our world-class insights, our innovation ecosystem, our brand building and our distribution capabilities, we have put investment behind building a well-established portfolio of global brands spanning all three new categories. Beyond that, because of our global footprint and since a number of our key markets remain closed to smokeless alternatives, we recognize that we must keep investing to drive value from combustibles through a well-balanced portfolio of brands across price tiers. Let me now give more detail on our new category launches. Beginning with Modern Oral, by far the fastest-growing new category, which has already achieved global scale. A recent study backed its position on the risk continuum, showing that smokers who switch completely to oral nicotine products are exposed to lower levels of toxicants similar to those who quit. Modern Oral performs very well in both traditional oral markets and in new markets where no oral nicotine tradition exists, and it is also highly profitable with a fast payback, as Soraya mentioned.
Tadeu Marroco
executiveAfter the launches that went well in Pakistan and South Africa, we keep seeing a really exciting chance for Modern Oral in emerging markets, because of how adaptable and affordable it is. Modern Oral is turning into a meaningful contributor to what our group delivers, as Velo keeps going from strength to strength. We're clearly the leaders in AME — close to six times the size of our nearest competitor — and we're capturing around 60% of category growth, which shows the opportunity that still lies ahead. Velo is a premium product, over-indexing on value and strongly outperforming our peers right across the region. Because BAT holds the leading position in European Modern Oral, we've brought our know-how and capabilities to the U.S. We were already confident that with the right product, we could make performance in growth in the U.S., and with Velo Plus that is now being realized. In the U.S., the Modern Oral category, worth around GBP 2 billion, has already overtaken the size of the legal vapor market. Over the next two years, it's expected to almost double. With the successful launch of Velo Plus, we have a step changed our U.S. performance and are now the fastest-growing Modern Oral brand. Velo Plus is driving triple-digit revenue growth and strong volume share gains.
Tadeu Marroco
executiveDuring May, Velo had captured nearly 9 percentage points in share from the time it launched. On an encouraging note, the most recent volume share figure we have from July sits above 17%. Such results testify to how good the product is, to the greater strength and speed of our distribution operations, and to sharper execution that RGM has made possible. We are enthusiastic about what lies ahead, and Velo Plus already ranks second by volume share across 11 states, among them New York and Texas, which combined account for roughly 10% of the whole U.S. category. Significantly, following our investment during the initial launch and rollout period, we anticipate that Velo Plus will produce a positive category contribution for the full year 2025. Turning to Heated Products, glo Hilo is a breakthrough innovation that, in our view, will reshape how glo is positioned within the premium segment, which makes up more than 80% of industry value. Glo Hilo carries a number of new and innovative features, among them fast ramp-up reaching just five seconds, a personalized LED screen, and connectivity with the myglo app, which enables customized sessions, find my glo, and remote locking. Together with new upgraded consumables offering enhanced taste and satisfaction, it comes closer to replicating cigarettes than anything we have ever achieved. At the end of 2024, we launched glo Hilo in Serbia.
Tadeu Marroco
executiveWe took what we learned — the insights and the critical lessons — and folded them into how we're approaching the rollout, starting with our June launch in Sendai. It's still very early days, but I'm encouraged that consumers are responding well to both the consumables and the devices. Glo Hilo is improving how consumers see glo, including brand equity and appealing design. On top of that, we've picked up 1.5 percentage points of volume share in just a few weeks at a premium price point. Importantly, Hilo marks the first time glo will also offer a two-piece device, launching as part of the national rollout in Japan this September. We'll keep rolling out glo Hilo in a targeted way across the largest heated value pools through the second half. We believe premium vapor done right is an untapped opportunity, one that offers greater differentiation and more potential for value generation. Vuse Ultra is our initial step, delivering a high-quality and satisfying experience alongside a connected and highly customizable offering. Key features include as small as new smart pods, which automatically adjust the device to consumers' preferred flavor settings, a clear view display to easily track battery and liquid levels, connectivity enabling find my vape, and a device lock further reinforcing Vuse position as a brand consumers can trust.
Tadeu Marroco
executiveVuse Ultra first went on sale online in Canada at the close of Q1, followed by a national roll-out starting in June. Early reactions from consumers have been favourable. Vuse Ultra is producing a solid gain on important attributes—premium, innovative and easy to use—and has picked up more than 2% of value share since that national launch. We recently introduced it in the U.K. and Germany, and further targeted roll-outs will continue through the second half. Now to the U.S., the biggest nicotine profit pool worldwide and the foundation of our business. That is precisely why getting back to growth there has been one of my main priorities. We have put money into reinforcing our portfolio, correcting price gaps and indexation. We have also tightened up how we execute—widening contract coverage, growing our sales force and enhancing revenue growth and management. Our reward programmes, supported by better digital capabilities. I am very pleased that value is starting to be generated by the steps we have taken to reinforce our portfolio and execution. Overall volume share rose 10 basis points, while value share climbed 20 basis points. Value share is improving broadly right across the portfolio. Lucky Strike, our value-for-money brand, remains the fastest-growing U.S.
Tadeu Marroco
executiveFor our combustible brand, value share was 60 basis points higher. Even with consumers feeling pressure on their wallets, value share for Natural American Spirit—our super premium brand—rose 10 basis points. The Newport brand family has stabilized thanks to the targeted launch of a soft-pack variant. In the U.S., I think we've turned a significant corner. Having made substantial investments, we're now well placed to build on that recovery and to contribute sustainably to group performance in 2025 and beyond. On regulation, we're encouraged that vapor directory and enforcement legislation has now passed in 18 U.S. states, and we look forward to these laws being implemented alongside stronger enforcement. Several states are now showing that well-constructed regulation can work against illicit vapor, with Vuse volume back to growth. We also remain cautiously optimistic about a more proactive federal approach to illicit vapor enforcement. The new administration has made clear that tackling illicit vapor is a key priority, and the FDA has already taken some important first steps—updating product classifications, closing loopholes for small shipments, and seizing illicit products. Although these actions have recently driven a reduction of more than 40% in vapor-related shipments to the U.S., the long supply chain means we have yet to see any meaningful impact on the ground.
Tadeu Marroco
executiveSo because of that, our 2025 guidance assumes no recovery at all in the legal vapor market. As I said before, we remain focused on tightening up execution, and digital transformation is a crucial enabler for us. With the strength of our strategic partnerships, BAT is ahead of the curve. Let me walk through four main highlights. First, we lead globally in cloud adoption, with 85% of hosting in the cloud delivered through strategic partnerships. Second, our groundbreaking partnership with Microsoft allowed us to build our enterprise data platform quickly, moving our global data infrastructure forward via MS Fabric and next-gen technologies. That gives us a data-first, agile organization, improving tools such as RGM and the effectiveness of marketing spend. Third, this year we opened our Gen AI Lab in Dubai, which makes BAT the first CPG company in the region's AI hub. We have already rolled out use cases including AskOmni, AI-powered sustainability bots, and advanced consumer insight tools. Finally, we have simplified our strategic technology partnerships, cutting IT run costs by 40% while keeping 99.9% uptime. We will keep driving BAT's digital transformation together with our partners, fueling growth, enabling productivity, and building a more sustainable business. Our strategic partnership with Accenture, announced recently, is a clear example of our digital transformation in action.
Tadeu Marroco
executiveWe're moving our global shared service over to Accenture. Through this partnership, BAT gains access to Accenture's cutting-edge technology ecosystem, which includes Agentic AI solutions and its strategic collaboration with world-leading technology companies. Those capabilities are going to help us simplify our processes even more, speed up time to market, upskill our people, and lower costs across the medium to long term. On the other side, BAT's industry-leading expertise in supply networks will bolster Accenture's global supply chain and operations. This marks a key step toward turning BAT into a future-ready, digitally-enabled organization driven by strategic partnerships. To wrap up, as Soraya pointed out, we remain on track to deliver our full-year guidance. As we look toward 2026, I have confidence that we'll build on our underlying momentum through the key growth drivers, among them the continued momentum in the U.S., AME, and Velo. Lapping Bangladesh combustibles headwinds. A further rise in new category contribution. A step up in efficiencies from our new Fit to Win program, delivering 3%-5% revenue growth and 4%-6% adjusted profit from operations growth. Last, I'd like to offer a few key takeaways from our results. We've returned to revenue and profit growth in the U.S., which is a critical milestone. Velo stands as the fastest-growing brand within the fastest-growing new category, with real momentum in the U.S.
Tadeu Marroco
executiveAnd across the world. We're boosting profitability throughout our portfolio of new categories. Our R&D ecosystem keeps turning out exciting premium innovations. We keep strengthening our proactive stance on regulatory affairs so we can open up new markets and establish a sustainable, level, competitive playing field. Meanwhile, our digital transformation is speeding up, improving how we execute, and unlocking additional efficiencies and agility. All of this is done with a focus on cash, returning GBP 17 billion to shareholders over the last three years while continuing to deliver it. While there's more to do, I'm confident we have the right strategy, capabilities, and people to deliver a profitable transformation. I'm excited about what lies ahead for BAT, and I believe we will deliver long-term sustainable growth and value for all our stakeholders. Thank you for listening. Victoria will now join us on the stage for the question and answer session.
Victoria Buxton
executiveThanks, Tadeu and Soraya. Morning, everybody. Should you be with us on the webcast, you're able to type your questions straight into the online question box. Should you be on the call, just press star one on your telephone keypad. Tadeu and Soraya are both very happy to take your questions today, and I'll now hand things over to the operator.
Operator
operatorThanks. We’ll take our first question now from Simon Hales at Citi. Simon, please go ahead.
Simon Hales
analystThank you. Good morning, Tadeu, Soraya, and VB. I have two or three questions, if possible, please. Tadeu, could we talk a bit more about the early performance you're seeing from the glo Hilo launch in Japan? Obviously, you referenced it in your presentation in terms of the recent share gain you're seeing. Qualitatively, what feedback are you getting on the ground from those Japanese consumers? How does it vary, if at all, from what you saw in the test market in Serbia? How should we think about the scale of the rollout into other key markets through the rest of the year? What % of your key heated tobacco markets do you expect to be in by the end of the year? Secondly, on Modern Oral, clearly, a very strong performance coming through from Velo Plus in the U.S., and you referenced the further share gain that you've seen coming through into July as well. Have you seen any change in momentum for the brand as you exited the quarter and came into July, given that the biggest competitor on the ground is now back on shelf and perhaps being a little bit more aggressive in its point of sale promotional activity?
Simon Hales
analystThen just to clarify something for Soraya regarding Fit to Win. I believe you mentioned that no upfront costs will occur before 2026 for that initiative. Nothing is scheduled in the back half of this year. Is that correct? My assumption is that the GBP 500 million goal across three years is a gross savings figure, and a portion of it should be expected to go back into the business as reinvestment.
Tadeu Marroco
executiveThanks, Simon, for those questions. Regarding glo Hilo in Japan, consumer feedback has been very positive. Its portfolio was far more tailor-made for Japanese consumers than the one we launched in Serbia. We've done a great deal of work to reach highly competitive offers, because it isn't only about the device. The device is clearly a huge step change compared with what we've offered so far in Japan and anywhere else across the group. The consumables matter a lot too. We believe we have a new technology in the consumables that, together with the device's heating mechanism, delivers — as I said in my presentation — the closest thing to smoking a cigarette we can get in an HP product. That is resonating well with consumers. You need to keep in mind that in Sendai we don't yet have the two-piece device, and even so, in a few weeks we've reached 1.5% at a premium level we've never been able to compete with glo on before when it comes to consumables pricing. That's quite exciting. As for the rollout over the rest of the year, we're just starting now, since, as I mentioned, September in Japan, and we'll be reaching the highest profit pools in the HP category through December, though it will only be early stage.
Tadeu Marroco
executiveThe effect of that will likely be visible across 2026. Turning to Modern Oral — yes, Velo Plus has us genuinely thrilled. Momentum for the brand continues. At launch, like with any new U.S. introduction, there's a price list, and we use some discounts to encourage trial among consumers. What we observe is that after trying it, retention remains at an exceptionally high level — 70% retention. Since launch, we've been trimming those discounts. Even so, market share keeps rising along with repurchase at the point of sale. Overall, we're strongly behind Velo Plus's future growth in the U.S. On pricing today, once you exclude the leading brand, we already over-index against the remainder of the market. Looking at value share and the trend we're observing, we're quite near securing the number two spot. We are — and we'll return to positive contribution as early as 2025, which demonstrates that this category has the right product, the right focus, and the right execution.
Tadeu Marroco
executiveThe payback period can be quite brief. Overall, that’s something we’re very enthusiastic about. Soraya.
Soraya Benchikh
executiveHi, Simon. Thanks for asking. Let me provide a bit of context about Fit to Win. I think we've done a very good job over the years of removing costs from the business. Fit to Win is a little different. Its main purpose is really to make the organization future-fit. Essentially, we're reviewing many of our key work processes across the organization and embedding digital decision-making into our processes. We're carrying out a full review of indirects. We're also examining our routes to market to make sure they're transformed in line with the business transformation we're going through. To answer your question on costs, we will incur some costs in 2025, but this is fully included in our guidance. The GBP 500 million will be an annualized saving that we will reach at the end of 2028. Yes, we will be looking to reinvest to fuel the growth behind our innovations.
Simon Hales
analystMuch appreciated.
Operator
operatorThanks. We’ll take our next question from Damian McNeela at Deutsche Numis. The line is yours — go ahead.
Damian McNeela
analystHi there, good morning everyone, and thanks for taking the questions. My first question is really about whether you can give us a bit more color on how the vapor business is performing in the AME region. I think you flagged some challenges in Canada as well as the transition that's happening in some of the bigger markets such as the U.K. I was just wondering whether you could share some thoughts on what's happening on the ground and what your expectations are for vape in those markets over the medium term. Then just on U.S. vape, and some clarification on the 40% reduction in shipments that you've seen. I guess it's very difficult to have any accurate number, but could you give us a sense of what that means in terms of when we might expect to see a change on the ground when it comes to illicit availability, please?
Tadeu Marroco
executiveAlright, Damian. So, vaping AME's results have taken a big hit because of Canada. In Canada, Quebec — the biggest province, and the place where the bulk of sales occur — has brought in rules that prohibit every flavor, yet enforcement is essentially nonexistent. We're seeing illegal products flood in, and beyond that, there are these large-tank, large disposable brands, and given duty of care, we can't offer anything even close to that. So as a result, we had a strong business. On tracked channels we're still doing fairly well, but a hidden market exists that doesn't appear in tracked channels, and it's flooding the market, which makes it extremely difficult for responsible companies to compete on a level playing field. In fact, because of this, AME's headline numbers take a hit. Something interesting is happening in Europe: the trend is shifting away from mods toward closed systems. As you'd expect, when you sell mods you're selling a device, so NTO per unit is higher than when you're selling pods in the closed system. At first, this will translate into an impact on the business's top line.
Tadeu Marroco
executiveConversely, over the longer term this shift is genuinely good for BAT. Consider the U.K.: our total vapor share, mods included, sits at a bit above 10%. If you look specifically at closed systems, our share there is 33%. With this transition maturing — and as you're aware, the U.K. has only just prohibited mods, and the anticipation is that closed systems will increasingly take the place of mods as time goes on — we ought to see growth come back in those markets. France is showing the same pattern. Even so, in France closed systems already represented a large portion of the market, and our position there is very strong, at close to 60% market share. Germany has followed suit. Even with no prohibition in place there, consumers are moving of their own accord from mods to closed systems, since closed systems keep improving on satisfaction. Consumers also get a better economic and financial equation, because there's no need to purchase a device. Instead, you simply buy pods as time passes. One more interesting thing we're observing: as we mentioned earlier, our intention was to investigate launching a premium segment — similar to what we have in Heated Products and in cigarettes — throughout vapor, where it doesn't really exist.
Tadeu Marroco
executiveVuse Ultra was our initial foray, and the results we're seeing on the ground are genuinely encouraging. It's still early, but we captured over 2% of value share in Canada despite all the complicated circumstances I mentioned to you. We're also witnessing very strong traction in Germany, where we launched only a few weeks ago. We've just launched in the U.K., and we'll keep rolling out. That's the situation in AME and vapor. In the U.S., prediction is very hard, because what we're seeing on the ground is that some of these key brands can no longer be found at certain points of sale. They're running out of the shelves. There are so many other offerings of these kinds of products, illegal vapor products that essentially target youth with flavors like bubblegum, rainbow candy — things that absolutely shouldn't be in the market in the first place. We are still seeing those products there. The encouraging fact on this is that the new administration, the new Secretary of HHS, the new Chair of the FDA has been very vocal about putting as a priority the annihilation, if you want, of these non-responsible and non-conform brands.
Tadeu Marroco
executiveBeyond just the narrative, but what we’re beginning to observe on the ground, that 40% reduction in shipment is one of the data points. We’re aware that certain of those manufacturers misdeclare what they bring in, they undervalue their shipments. They know that full well. They’re taking steps to deal with that. It comes down to consistency. On the first angle of your question, we need to see consistent multi-agency work on that, which for now appears to be the case. At the same time, we have to wait, because there’s a long supply chain in the U.S., to see a meaningful impact. That’s one side of the equation. The other side of the equation is ultimately to get the FDA addressing the approval process, because the root cause of all this illegality is the fact that U.S. consumers don’t get enough smokeless products. That’s another thing we hope the FDA will address over time.
Damian McNeela
analystThat's great. Thanks a lot, Tadeu.
Operator
operatorMuch appreciated. Rey Wium from Anchor Stockbrokers has the next question in the queue. The line is yours.
Rey Wium
analystMorning, Tadeu, Soraya, and Victoria. Let me begin with the U.S. On the combustible side, it's really encouraging to see the volume decline has now moderated to 7.6%. I'd just like to know what your indication is for the rest of the year. Could this rate of decline ease even more, or is that basically where we're going to stabilize? My other question is on the very strong performance from Velo Plus in the U.S. I'd just like to know — obviously, you're still awaiting approval for, I guess, Velo 2. If you could give us any update on that. Given that Velo Plus is already performing so well, what are you thinking around Velo 2 once it becomes available? My last question is just a clarification, because honestly, I'm a bit confused about your adjusted EPS number. You show it as $162. I also see a number that I can't find anywhere in the release, which is the $155.5, which excludes or adjusts for Canada, including currency. Maybe you could just help us understand what the real number is that you're looking at and what you want us to focus on, because the adjusted EPS on that basis is actually down 2.4% and not up.
Rey Wium
analystIt would really help us out to gain a bit of clarity on how we should be approaching this particular item.
Tadeu Marroco
executiveThanks for the question. Soraya, we've already addressed the adjusted EPS item. On volume, from an industry standpoint, we're observing a modest uptick versus last year. It isn't significant. At this same point last year, the decline was 8.5% overall. This year, it's closer to 8%. I don't expect we'll see a meaningful deviation from that until year-end. Consumers remain under considerable pressure. Confidence levels are still weak. Obviously, that's been partly offset by the reduction in gas prices. We observe an inverse correlation between gas price and U.S. cigarette sales, which recently has been supportive of volumes. The other major uncertainty concerns how much additional enforcement against illegal vapor disposable products can be carried out in the U.S., since we also know that some of the softness in the combustibles business ties to the availability of these products in the market. Obviously, if you anticipate some enforcement, at minimum the switching from combustibles into these products will likely be reduced. Regarding Reynolds, we're very pleased with how we performed.
Tadeu Marroco
executiveWhat this demonstrates is that every commercial initiative we've launched over the past two years is connecting with customers, and the results on the ground are strong. The rise in market share and the gain in value share make that clear. Our price mix has held up very well. Of course, we made certain choices, largely price-related, during 2023 and 2024, and that leaves this half year facing a somewhat easier comparison. That's the reason we're flagging that the second half should be somewhat stronger — the comparison for U.S. combustibles broadly. On the whole, we're quite confident we can sustain the momentum. Keep in mind what we've consistently stated: for us to return to the 3%-5% group algorithm on revenue, what's required is for combustibles as a group to deliver between 1%-2%. Within that equation, the U.S. will land between 0%-1%. We're running well ahead of that. Over the medium to long run, provided we can at minimum deliver 0%-1%, every possibility is open to us once the other two regions complement it, and we now expect to lap Bangladesh starting next year. So that gets us back to the likes of 2% plus new categories to return to the algorithm.
Tadeu Marroco
executiveThat covers the combustibles side. With Velo Plus, the clearest point of difference is obviously how it was executed — Reynolds taking a product from nothing to 135,000 outlets, and doing that in six months, is really remarkable. Beyond that, this is the product that delivers more moisture to the market. The Velo 2.0 you mentioned — that's what we call it here too — brings even more moisture, and it's the version we have in Europe that's doing very well. That's why we were pointing to that case. We don't say much about ex-U.S., but the reality is our Velo brand's volume is nearly six times larger than the second place player in that region. This product will complement Velo Plus, because Velo Plus has been so successful that this product will be complementary. It's very difficult to predict when this gets approved. It comes back to the point I made just recently in the previous answer. This is one area the FDA needs to address — the rhythm of approval — because millions of submissions were made over the last five years with only a handful, 25 or so MGOs, given, which is basically not enough to address all the consumer needs in the U.S.
Tadeu Marroco
executiveThe reason is that we're noticing an increasing number of poly users here in the U.S. It would be great if the FDA could tackle that issue. That way, some of this process could be accelerated. This ensures that the success Velo Plus is enjoying right now can be sustained through the Velo pipeline we have outside the U.S.
Soraya Benchikh
executiveRegarding EPS, what you're essentially seeing is $162.1 on a constant currency basis. The $155.5 figure shown reflects the current basis. There's an adjusting item — that's our Canadian adjustment — but Victoria and her team will gladly give you a complete reconciliation. The figure to focus on is $162.1.
Operator
operatorThanks. We’ll take our next question from Gaurav Jain at Barclays. Please go ahead.
Gaurav Jain
analystMorning, Tadeu. Morning, Soraya. I have three questions. First, regarding your U.S. cigarette pricing, which ran almost 12% ahead of your large competitor — there was obviously plenty of talk about double drawback in the U.S. market, in press releases, and across all those newspaper articles. Reynolds came up a lot. Could you explain how double drawback is affecting the U.S. business, and how much its contribution to your portfolio has shifted on a YOY basis? That is my first question. My second question concerns your overall e-cigarette strategy: it looks like you have pulled out of a few markets, particularly in AME, such as Malaysia, which was called out. Is something larger going on with your global e-cigarette portfolio as a whole, in the way you think about it? My final question is about Velo Plus. Amazing growth in the U.S., 1.1 billion vouchers in one edge. If we simply extrapolate these market share trends — what you are highlighting and what we see in the scanner data — you could be doing around 6x this volume next year, assuming the market keeps growing and you capture your fair share. Do you have that kind of capacity, or will you hit capacity shortages at some point of time?
Gaurav Jain
analystThanks.
Tadeu Marroco
executiveI'll begin with the drawback. This is a legal framework that has existed for a long time, designed to encourage manufacturing within the U.S. and create jobs. That is precisely what Reynolds is doing. This legal framework gives the top line a positive boost, but even without the duty drawback we would still be growing, since three major drivers sit behind that. The first, and the more significant one, is the performance itself. It comes down to the fact that our market share and value share are expanding. Our price mix is very strong. And we have beaten the market when it comes to volume. Looking at the industry overall, as I mentioned, the decline is closer to 8%-8.5%. Our decline was smaller than that. Taken together, what I refer to as performance is stronger, and that is the main driver. As I said more recently in the earlier question, we are up against a softer competitor because decisions we made in 2023, 2024 led to some inventory moves. That too adds to the very high growth rates you observed at the combustibles level. Lastly, there is the drawback, with Reynolds behind it, offsetting all this structural volume decline in the U.S. by compensating through additional exports from the U.S.
Tadeu Marroco
executiveTurning to other markets, which creates additional jobs and, even more crucially, means purchasing additional leaf too, and that helps U.S. farmers. That covers the first question. I'll move straight on to Velo Plus, since I need your assistance to get a better grasp of the second one. On Velo Plus: every share we're citing reflects consumer offtake, not shipment shares. That's correct. Our growth is rapid, and we should keep in mind that we started from a really tiny position at the back end of last year. We hold only about 6, 7% of the market. As I mentioned, our most recent figure for July has already reached the 17% mark. As I said, because we've been so deeply established in this category outside the U.S., launching Velo Plus lets us relocate machinery and cut short the lead time needed to build that machinery. We're very well set up for the growth pace we're seeing with Velo Plus. We don't anticipate any kind of difficulty on that front in the U.S. Now, the second question is.
Soraya Benchikh
executiveI’ll try to assist a bit here, Gaurav, on that second question. If I got it right, you’re asking about certain AME resource-allocation choices we made. What we’ve essentially needed to do is set priorities, since we’re launching innovations across all 3 categories. This year we have many innovations—Velo Plus in the U.S., Velo continuing globally, Vuse Ultra, and glo Hilo—and those require substantial investment. We’ve made some decisions that are purely about allocating resources by priority, essentially, in order to fund the investments and the biggest profit pools. That’s really what it comes down to. It isn’t truly taking away from these markets. It’s simply a matter of concentrating our resources so we can drive growth across every one of our innovations.
Tadeu Marroco
executivePart of this is ultimately about exiting, so I believe Malaysia vapor was what you meant. Yes, we had to leave Malaysia vapor, since that’s another market where enforcement became entirely impossible. Without enforcement, competing is extremely difficult. If the playing field isn’t level and you then adapt to that situation, we need to be smart about how our resources are deployed. We’ll make certain decisions if that happens. We try to engage with the government as early as possible to deal with the regulatory environment. If we can’t manage that, we have to make our calls. Malaysia vapor is one of them.
Gaurav Jain
analystI really appreciate it.
Operator
operatorMuch appreciated. Faham Baig of UBS is our following questioner. The floor is yours.
Faham Baig
analystGood morning, team, and thanks for the detailed presentation and the Q&A. I have a couple of questions, if I may. First, top line guidance has now been raised twice over the last two months, yet the EBIT outlook keeps getting reiterated. Could you go a bit deeper on where those incremental investments are going — the ones you hadn't budgeted for at the start of the year — and how you expect them to pay back in 2026? Second, can you remind us where things stand on ITC hotels? I know you've shared your view on this asset before, but where are we in the process of divesting that stake, please? Thank you.
Soraya Benchikh
executiveAll right, let me pull that up. Thanks, Faham. First off, I'd say the H1 results make us very, very happy. Let me start with the top line, then I'll get into the EBIT guidance. On the top line, when you look at that 1.8% growth, keep in mind we're up against the U.S. investment from H1. That 1.8% really works out to 1.4% growth. So we're weighted toward the second half, since we have a lot of innovations coming out, as we showed in the presentation. Also worth noting: the 1.5%-2.5% EBIT guidance is unchanged, even though we're at the top end of our NTO growth. Those innovations are there, and we're putting money behind the rollouts. It's not that we didn't see this coming, but we want to keep the flexibility to put in more funding to fuel growth further as we head into 2026. Another thing to keep in mind is that tariffs have had some effect. It hasn't been major, but we've absorbed it within our guidance. The key reason is that we want to preserve our ability to raise investments behind the innovations.
Soraya Benchikh
executiveAs you're aware, the innovations include the Vuse Ultra rollout and glo Hilo, which we're rolling out in the second half of this year, and obviously there's continued momentum behind Velo Plus in the U.S. and Velo globally.
Tadeu Marroco
executiveI'm not sure whether you'd like to add anything. No, I believe that's correct. I'll simply note that we find ourselves in a position unlike any we've had before. As a company, we now have products that are very, very competitive across every single category. That's very exciting. We discussed this at the CMD in October last year—all the efforts, all the strategic partners we were leveraging—and we're now seeing some of those products reach the market. Soraya just mentioned them, and it's a very strong position to be in; we're very pleased with that. Obviously, this calls for more discipline when it comes to investing, and those efforts will translate into future growth drivers for the company, which supports our guidance going forward on both top line and bottom line. On hotels, on ITC hotels, I've said this before and I'll keep saying it: strategically speaking, we don't intend to be shareholders in a hotel chain in India or outside India. The fact is that there are some bureaucratic steps that need to go through, in terms of the way that our sharehold—that dates back to early 1900.
Tadeu Marroco
executiveAs I explained earlier, there are occasions when unlocking those shares takes more time for us—securing the necessary approvals in the appropriate forums, which in this instance means the Central Bank in India, so that a transaction can take place. When we reach that point, we will be considering it, since this will help us return to the corridor of 2.5 to 2 times by the end of 2026. Our plan is to apply the proceeds from the hotel toward further de-leveraging the company.
Faham Baig
analystThanks, everyone.
Operator
operatorThank you. Andrei Andon from Jefferies has our last question. You have the floor.
Andrei Andon
analystGood morning, Tadeu, Soraya, and VB. Thanks for taking my questions. I have a couple, please. First, on Modern Oral in Europe, you benefited from most of the category growth in H1. Could you tell us a bit more about what you've done to protect that advantage in Europe, given that a competitor has become more aggressive about growth outside the U.S.? Second, on U.S. Modern Oral, I see that Velo Plus is already in 135,000 outlets, which I believe is ahead of the earlier target for fiscal 2025. Are there any further distribution gains still to come in H2, or are you satisfied with the current distribution base? Thank you.
Tadeu Marroco
executiveAlright, thanks Andrei for that question. Regarding Velo Plus, I'll take the second part of it first. We're present in 135,000 outlets, and we account for slightly over 9% of the category's value. There isn't really much need for us to push far past that point. What we're observing is that many retailers are sourcing from wholesalers since they want to stock the product, and those outlets aren't necessarily being serviced directly by us. It wouldn't shock us if that figure climbs higher, though we already regard it as an optimal number. Right now our attention is on building brand awareness, since it remains low—which also shows there's more upside for the brand—and on driving trial, because as I mentioned, once a consumer samples the product, retention levels are very high. Keep in mind that in the U.S., Modern Oral average daily use is three pouches, whereas AME as a region sits at six pouches, and Sweden, a highly mature market, is at 12 pouches. The category has plenty of room to grow, as long as you deliver a satisfying product, and Velo Plus appears to be doing exactly that as we speak.
Tadeu Marroco
executiveThat's why we see the category as having room to nearly double over the coming couple of years. Regarding Modern Oral beyond the U.S., sure, plenty of new competitors are entering — the more established players, but new ones too, since, as I mentioned, it's the category growing fastest. The new category also checks the box in several respects. On the risk continuum, it's likely among the lowest risks involved. It sits very close to nicotine replacement therapy. There's no inhalation. On affordability, you can target places like emerging markets, for instance, since no device is involved there. On margins, if anything, they're even higher than cigarettes. Clearly, there's a lot of appeal there. What we're doing — you just saw one of the slides I showed in my presentation. I was covering one of the Velo innovations that we're launching in the market over the next couple of months. It's about us sustaining the momentum and being able to give consumers more innovative products around that, plus spending behind brand building. We've been doing that diligently for a number of years now.
Tadeu Marroco
executiveA number of the choices we've discussed regarding allocating resources are aimed squarely at backing Velo's expansion, and Velo keeps getting stronger and stronger. All right.
Victoria Buxton
executiveAppreciate the questions, everyone. Unfortunately, we’re out of time at this point. Any questions still left over will be handled by the IR team online. So with that, I’ll turn things back over to Tadeu for some closing remarks.
Tadeu Marroco
executiveThanks to everyone for tuning in today and for the questions you sent our way. As we wrap up, I want to say that we remain on course to meet our guidance for the full year, since our H1 results came in a touch better than what we had expected. As I look toward 2026, I have confidence that the right building blocks are now in place for us to achieve our midterm algorithm. We'll keep rewarding shareholders by way of robust cash returns—this covers our progressive dividend as well as a sustainable share buyback—and we'll deliver growth over the long term along with value creation. Thanks once more for being with us.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete British American Tobacco p.l.c. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to British American Tobacco p.l.c. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in British American Tobacco p.l.c. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.